fda glp-1 warning letters october 2025 CDER Jump 50% in FY — What That Means for Industry FDA Issues Five Warning Letters

Continuous Expansion of Research and Application Scenarios At present, its application has been extended to fields such as cellular antiaging and neuroprotection

Nearly 7% of the overweight or obese patients taking semaglutide had NAION, compared to only 0.8% of patients who were not taking semaglutide

found that IDO1 activity in obese mice disrupts the intestinal mucosal barrier, triggers chronic inflammation, and interferes with lipid metabolism, worsening obesity-related metabolic diseases (121)

GLP-1 agonists are most often used by people with type 2 diabetes to manage blood sugar levels, but in recent years, theyve become a top treatment choice for people with overweight or obesity for weight management